This HTML5 document contains 47 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
wdthttp://www.wikidata.org/prop/direct/
schemahttp://schema.org/
skoshttp://www.w3.org/2004/02/skos/core#
rdfshttp://www.w3.org/2000/01/rdf-schema#
wikibasehttp://wikiba.se/ontology#
phttp://www.wikidata.org/prop/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
xsdhhttp://www.w3.org/2001/XMLSchema#
wdshttp://www.wikidata.org/entity/statement/
wdhttp://www.wikidata.org/entity/

Statements

Subject Item
wd:Q66065735
rdf:type
wikibase:Item
schema:description
ensayu clínicu klinisch onderzoek клінічне випробування clinical trial
rdfs:label
Study to Evaluate the Efficacy/Safety of IPI-549 in Combination With Nivolumab in Patients With Advanced Urothelial Carcinoma (MARIO-275) Study to Evaluate the Efficacy/Safety of IPI-549 in Combination With Nivolumab in Patients With Advanced Urothelial Carcinoma
skos:prefLabel
Study to Evaluate the Efficacy/Safety of IPI-549 in Combination With Nivolumab in Patients With Advanced Urothelial Carcinoma (MARIO-275) Study to Evaluate the Efficacy/Safety of IPI-549 in Combination With Nivolumab in Patients With Advanced Urothelial Carcinoma
schema:name
Study to Evaluate the Efficacy/Safety of IPI-549 in Combination With Nivolumab in Patients With Advanced Urothelial Carcinoma Study to Evaluate the Efficacy/Safety of IPI-549 in Combination With Nivolumab in Patients With Advanced Urothelial Carcinoma (MARIO-275)
p:P1476
wds:Q66065735-FD3E49F1-9151-4798-B5C5-69C4165E8377
wdt:P1476
A Phase 2, Multicenter, Randomized, Double-Blind, Active-Control Study to Evaluate the Efficacy and Safety of Nivolumab Administered in Combination With IPI-549 Compared to Nivolumab Monotherapy in the Treatment of Patients With Immune Therapy-Naïve, Advanced Urothelial Carcinoma
p:P582
wds:Q66065735-6AFEC424-24A0-4D32-BF13-5C9C4D82CD33
wdt:P582
2020-11-01T00:00:00Z
p:P31
wds:Q66065735-9391D0DA-F653-4BE0-AF5F-594E0079EE73
wdt:P31
wd:Q30612
p:P580
wds:Q66065735-7058268A-20FD-427B-AF7F-6CBCEFEA81B1
wdt:P580
2019-06-01T00:00:00Z
p:P6153
wds:Q66065735-42AEE7A9-F492-4E9A-85B9-17792F1161D5 wds:Q66065735-69369C05-F1EA-4169-A10B-E1D7E3AFBFFE wds:Q66065735-34BC8419-E781-4986-8BFA-77033135506B wds:Q66065735-3997CD2E-CD44-41F0-845B-7568B1FF591E wds:Q66065735-0E26994A-982E-441C-87CE-369F59295A39 wds:Q66065735-D476A4A2-B1A6-4E38-93C2-8BF4DD44ECE3 wds:Q66065735-E84CB916-826E-4D47-90D9-D3DF6BBB3676
wdt:P6153
wd:Q3151784 wd:Q349055 wd:Q30269666 wd:Q30282164 wd:Q30296137 wd:Q12752817 wd:Q6905066
p:P2899
wds:Q66065735-529B0377-2742-464D-A71B-EB2251AEB3B9
wdt:P2899
18
p:P1050
wds:Q66065735-3A3867B6-CDD2-4091-85CA-40DE8F5481AF
wdt:P1050
wd:Q33525
p:P1132
wds:Q66065735-08A0B17E-AAD6-4CB3-A87F-0EC9EE7A23E9
wdt:P1132
160
p:P767
wds:Q66065735-2E3DFEAC-E059-4AEE-835A-3E535D7CF9D4
wdt:P767
wd:Q266423
p:P8363
wds:Q66065735-2D279BBC-1853-4AC4-A3C0-362C601DC0AA
wdt:P8363
wd:Q78089383
p:P3098
wds:Q66065735-72F8B110-4835-4827-98BD-5E9F7AD06B7E
wdt:P3098
NCT03980041
p:P6099
wds:Q66065735-85B95C01-DEBB-4522-BEAC-BFDCDCA907B9
wdt:P6099
wd:Q42824440